Menu

Latest News

The REFINE-MS trial will evaluate if people living with relapsing-remitting MS can take treatment less often while keeping their disease activity under control.

An AI technology is effective at planning the delivery of life-saving radiotherapy for cervical cancer and prostate cancer, according to results from a large international trial led by researchers at UCL and the London School of Hygiene & Tropical Medicine (LSHTM). For cervical cancer, 94% of deaths occur in low- and middle-income countries (350,000 women died in 2022). Ra ...

Analysis from the STAMPEDE trial shows that combining a PSA blood test with information about cancer burden at diagnosis predicts survival more accurately than PSA levels alone.
BREATHER+ results published in The Lancet HIV confirm that taking HIV medicines every day without breaks remains the best way to keep the virus under control.
Evidence from the PATCH and STAMPEDE trial networks broadens treatment options for people with prostate cancer who are starting long-term hormone therapy.